Literature DB >> 211040

Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.

I McConnell, G Klein, T F Lint, P J Lachmann.   

Abstract

Activation of the alternative complement pathway by human B cell lymphoma lines is correlated with the presence of Epstein Barr virus (EBV) in the cell genome. EBV-negative B cell lymphoma lines produce little activation of the alternative pathway as measured either by C3 deposition on the cell surface or C3 conversion and consumption of alternative pathway activity in the supernatant serum. By contrast, EBV-positive sublines derived by in vitro EBV conversion of EBV-negative parental lines produce considerable activation of the alternative pathway. This membrane-associated complement-activating mechanism reflects an EBV-induced membrane change in these cells and may provide a mechanism whereby EBV-transformed cells are controlled in vivo.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211040     DOI: 10.1002/eji.1830080702

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibody-independent complement activation.

Authors:  J A van Strijp; K P van Kessel; L A Miltenburg; A C Fluit; J Verhoef
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

Authors:  H Martin; I McConnell; B Gorick; N C Hughes-Jones
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

3.  Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

Authors:  H V Marquart; K Grønbaek; B E Christensen; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

4.  The isolation of the antibody moieties of immune complexes from serum by the pepsin digestion of conglutinin-anti-conglutinin complexes.

Authors:  P J Lachmann; M Macanovic; G D Harkiss; R G Oldroyd; J Habicht
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

Review 5.  Epstein-Barr virus (EBV), lymphocytes and transformation.

Authors:  J Zeuthen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

Review 6.  The role of antibody and complement in lysing virus-infected cells.

Authors:  J G Sissons; R D Schreiber; N R Cooper; M B Oldstone
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

7.  Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.

Authors:  J G Sissons; M B Oldstone; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

Authors:  O F Ramos; G Sármay; E Klein; E Yefenof; J Gergely
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

10.  Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.

Authors:  H Okada; N Wakamiya; N Okada; S Kato
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.